促肾上腺皮质激素型侵袭性垂体瘤与垂体癌常携带ATRX突变
本研究用免疫组化检测30例侵袭性垂体瘤(APT)和18例垂体癌(PC)的ATRX蛋白表达,并对免疫阴性者行ATRX基因测序。48例中9例(19%)ATRX免疫阴性,PC比例高于APT,促肾上腺皮质激素型肿瘤最高;9例均检出功能缺失性ATRX突变。结论提示ATRX突变多见于促肾上腺皮质激素型肿瘤,支持用ATRX免疫组化识别侵袭和转移风险患者。
要点
- 48例中9例(19%)ATRX免疫阴性,PC为5/18(28%)、APT为4/30(13%)。
- 促肾上腺皮质激素型肿瘤ATRX缺失7/22(32%),高于Pit-1谱系2/24(8%)。
- 9例ATRX免疫阴性者均检出功能缺失性ATRX突变,支持免疫组化筛查。
核心结论
- ATRX突变见于部分侵袭性垂体瘤和垂体癌,且在促肾上腺皮质激素型肿瘤中更常见。
- 研究结果支持通过ATRX免疫组化识别有侵袭性和潜在转移风险的垂体瘤患者。
研究设计与样本
- 研究纳入30例侵袭性垂体瘤和18例垂体癌,以免疫组化检测ATRX蛋白表达。
- 对缺乏ATRX免疫标记的肿瘤进一步分析ATRX基因突变状态。
主要发现
- 48例肿瘤中9例(19%)缺乏ATRX免疫标记。
- 垂体癌中ATRX缺失5/18(28%),侵袭性垂体瘤中4/30(13%)。
- 促肾上腺皮质激素型肿瘤ATRX缺失7/22(32%),Pit-1谱系肿瘤为2/24(8%)。
- 9例ATRX免疫阴性者均检出功能缺失性ATRX突变:无义突变4例、移码缺失4例、累及36个外显子中22-28个的大片段缺失3例。
- 2例垂体癌检出超过1个ATRX基因缺陷。
关键数值与推荐
- ATRX免疫阴性:9/48(19%);PC 5/18(28%),APT 4/30(13%)。
- 促肾上腺皮质激素型7/22(32%)对比Pit-1谱系2/24(8%)。
- 功能缺失性ATRX突变:无义突变4例、移码缺失4例、大片段缺失3例,均见于9例免疫阴性者。
临床怎么用
- 对侵袭性垂体瘤和垂体癌可考虑行ATRX免疫组化,辅助识别高风险患者。
- ATRX免疫阴性者应关注侵袭性和潜在转移风险,并考虑ATRX基因突变检测。
局限性
- 研究样本量有限,共48例肿瘤。
- 原文未报告随访、治疗反应及生存结局等临床关联数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of response to standard treatment. About 1% to 2% develop metastases being classified as pituitary carcinomas (PCs). For unknown reasons, the corticotroph tumors are overrepresented among APTs and PCs. Mutations in the alpha thalassemia/mental retardation syndrome X-linked (ATRX) gene, regulating chromatin remodeling and telomere maintenance, have been implicated in the development of several cancer types, including neuroendocrine tumors. OBJECTIVE: To study ATRX protein expression and mutational status of the ATRX gene in APTs and PCs. DESIGN: We investigated ATRX protein expression by using immunohistochemistry in 30 APTs and 18 PCs, mostly of Pit-1 and T-Pit cell lineage. In tumors lacking ATRX immunolabeling, mutational status of the ATRX gene was explored. RESULTS: Nine of the 48 tumors (19%) demonstrated lack of ATRX immunolabelling with a higher proportion in patients with PCs (5/18; 28%) than in those with APTs (4/30;13%). Lack of ATRX was most common in the corticotroph tumors, 7/22 (32%), versus tumors of the Pit-1 lineage, 2/24 (8%). Loss-of-function ATRX mutations were found in all 9 ATRX immunonegative cases: nonsense mutations (n = 4), frameshift deletions (n = 4), and large deletions affecting 22-28 of the 36 exons (n = 3). More than 1 ATRX gene defect was identified in 2 PCs. CONCLUSION: ATRX mutations occur in a subset of APTs and are more common in corticotroph tumors. The findings provide a rationale for performing ATRX immunohistochemistry to identify patients at risk of developing aggressive and potentially metastatic pituitary tumors.
引用
- Casar-Borota O, Boldt HB, Engström BE, et al. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. J Clin Endocrinol Metab. 2021. PMID: 33106857. doi:10.1210/clinem/dgaa749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。